AIM ImmunoTech Inc.
Last updated September 27, 2026
Organization details
- Legal name
- AIM ImmunoTech Inc.
- Former names
- Hemispherx Biopharma Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Ocala
- Headquarters state / province
- Florida
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AIM
- Primary stock exchange
- NYSE American
Identifiers
- SEC CIK
- 0000946644
- EIN
- 52-0845822
Board of directors
-
David I. Chemerow · DirectorSince 2025
-
Nancy Bryan · DirectorSince 2023
-
Stewart Appelrouth · DirectorSince 2023
-
Ted D. Kellner · DirectorSince 2024
-
Thomas K. Equels · Director · CEO & PresidentSince 2023
-
William M. Mitchell · DirectorSince 2024
Chief executives
Thomas K. Equels
· CEO & President
Dates unknown
Director election results
Annual meeting of December 17, 2024. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
49.2%
-
50.1%
-
51.4%
-
51.9%
-
54.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $13,456
- 4 purchases by 1 insider
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 17, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +24,000 | $0.21 | $4,992 |
| Sep 16, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +11,000 | $0.21 | $2,310 |
| Sep 15, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +22,000 | $0.22 | $4,862 |
| Sep 14, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +5,900 | $0.22 | $1,292 |
| Mar 12, 2026 | Thomas K. Equels Director, Officer (CEO & President) | Derivative conversion | +25,000 | — | — |
| Mar 12, 2026 | David I. Chemerow Director | Derivative conversion | +25,000 | — | — |
| Feb 5, 2026 | David I. Chemerow Director | Grant or award | +2,800 | $1.23 | $3,444 |
| Jun 13, 2025 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +107 | $7.70 | $824 |
| Jun 12, 2025 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +103 | $8.70 | $896 |
| Apr 11, 2025 | William M. Mitchell Director | Open-market purchase | +196,851 | $0.03 | $5,906 |
| Apr 11, 2025 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +1,968,504 | $0.03 | $59,055 |
| Apr 11, 2025 | Ted D. Kellner Director | Open-market purchase | +1,968,504 | $0.03 | $59,055 |
| Apr 4, 2025 | Thomas K. Equels Director, Officer (CEO & President) | Open-market purchase | +41,000 | $0.06 | $2,460 |
| Apr 4, 2025 | Rodino Peter W III Officer (COO, Secretary, Gen. Counsel) | Open-market purchase | +500 | $0.09 | $45 |
| Mar 14, 2025 | William M. Mitchell Director | Grant or award | +44,899 | $0.12 | $5,388 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.